Bristol-Myers' Phase III lung cancer trial of Opdivo meets endpoint
Bristol-Myers Squibb has stopped CheckMate -057, an open-label, randomised Phase III trial, which is evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non small cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Taxotere